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ABSTRACT
VGLL proteins are transcriptional co-factors that bind TEAD family
transcription factors to regulate events ranging from wing
development in fly, to muscle fibre composition and immune
function in mice. Here, we characterise Vgll3 in skeletal muscle. We
found that mouseVgll3was expressed at low levels in healthy muscle
but that its levels increased during hypertrophy or regeneration; in
humans, VGLL3 was highly expressed in tissues from patients with
various muscle diseases, such as in dystrophic muscle and alveolar
rhabdomyosarcoma. Interaction proteomics revealed that VGLL3
bound TEAD1, TEAD3 and TEAD4 in myoblasts and/or myotubes.
However, there was no interaction with proteins frommajor regulatory
systems such as the Hippo kinase cascade, unlike what is found for
the TEAD co-factors YAP (encoded by YAP1) and TAZ (encoded by
WWTR1). Vgll3 overexpression reduced the activity of the Hippo
negative-feedback loop, affecting expression of muscle-regulating
genes including Myf5, Pitx2 and Pitx3, and genes encoding certain
Wnts and IGFBPs. VGLL3 mainly repressed gene expression,
regulating similar genes to those regulated by YAP and TAZ.
siRNA-mediated Vgll3 knockdown suppressed myoblast
proliferation, whereas Vgll3 overexpression strongly promoted
myogenic differentiation. However, skeletal muscle was overtly
normal in Vgll3-null mice, presumably due to feedback signalling
and/or redundancy. This work identifies VGLL3 as a transcriptional
co-factor operating with the Hippo signal transduction network to
control myogenesis.
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INTRODUCTION
The Hippo signal transduction network regulates development,
stem cell identity and function, cell proliferation, and organ and
body size (Hansen et al., 2015; Piccolo et al., 2014; Tremblay and
Camargo, 2012). Hippo proteins also have major functions in
skeletal muscle (Wackerhage et al., 2014), where the Hippo
effector YAP (gene symbol YAP1), but also other proteins such
as the YAP paralogue TAZ (gene symbol WWTR1), vestigial-like
factors (VGLL) 1–4 and the TEA domain (TEAD) 1–4 transcription
factors, have been linked to both developmental and regenerative
myogenesis (Chen et al., 2004; Gunther et al., 2004; Judson et al.,
2012; Maeda et al., 2002; Mielcarek et al., 2002, 2009; Sun et al.,
2017; Watt et al., 2010). For example, both YAP and TAZ are
expressed in muscle stem (satellite) cells, where they promote
proliferation, and while TAZ enhances subsequent myogenic
differentiation into multinucleated myotubes, YAP inhibits this
process (Judson et al., 2012; Sun et al., 2017). This transcriptional
network also plays a role in genetic muscle disease (Bertrand et al.,
2014; Judson et al., 2013) and development of rhabdomyosarcomas
– sarcomas with characteristics of skeletal muscle (Mohamed et al.,
2016; Slemmons et al., 2015; Tremblay et al., 2014). Hippo and
VGLL proteins also affect muscle fibre type distribution (Honda
et al., 2017; Tsika et al., 2008), and can cause skeletal muscle
hypertrophy (Goodman et al., 2015; Watt et al., 2015). Finally,
Hippo proteins are candidate regulators of adaptation to exercise
training (Gabriel et al., 2016).
The term ‘Hippo’ stems from a kinase-encoding gene whose
mutagenesis resulted in the puckered appearance of the head in fly,
reminiscent of the skin of a hippopotamus. At the centre of the Hippo
signal transduction network are the transcriptional co-factors YAP
and TAZ that bind and co-activate the TEAD1–TEAD4 transcription
factors to regulate gene expression. The Hippo pathway is a signalling
cascade where the kinases MST1 and MST2 (encoded by STK4
and STK3, respectively) regulate LATS1 and LATS2 by
phosphorylation. In turn, LATS1 and LATS2 inhibit YAP/TAZ-
dependent gene regulation through inhibitory phosphorylation of
multiple serine residues, which prevents nuclear translocation of
YAP/TAZ, and so interaction with TEAD1–TEAD4 (Hansen et al.,
2015). However, YAP/TAZ and TEAD1–TEAD4 are not only
regulated by the Hippo pathway, but also by many other signalling
systems, including the AMPK pathway, mechanotransduction, G
protein-coupled receptors andWnt signalling, that communicatewithReceived 28 September 2018; Accepted 3 May 2019
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the Hippo pathway (Hansen et al., 2015). This is why the term ‘Hippo
signal transduction network’ arguably best describes the overall
signalling system whose main molecular function is transcriptional
regulation through the TEAD1–TEAD4 transcription factors.
The Vgll1–Vgll4 genes in mammals are homologous to the
vestigial gene in fly and also bind TEAD family transcription
factors, so VGLLs can operate in a similar manner to YAP and TAZ
to organise transcription. Vestigial and VGLL proteins use their
TONDU domain (Vaudin et al., 1999) to bind to TEAD proteins via
two interfaces at the same TEAD site also bound by YAP via three
interfaces (Pobbati et al., 2012). Loss of vestigial reduces the wings
of flies to vestiges (reviewed in Simon et al., 2016), which requires
the TEAD homologue scalloped (Halder et al., 1998). In mammals,
Vgll1–Vgll3 have one TONDU domain, and are expressed in a
tissue-specific fashion, while Vgll4 has two TONDU domains and is
ubiquitously expressed. Functionally, VGLL4 is a YAP-TEAD
repressor or antagonist, whereas VGLL1–VGLL3 have been
suggested to be ‘selector’ genes that specify cell and tissue types
(Koontz et al., 2013). Recently, ETS1 was identified as an
additional VGLL3-binding transcription factor, suggesting that
TEAD proteins are not the only transcription factors that are co-
regulated by VGLLs (Simon et al., 2017). As transcriptional
regulation through TEAD1–TEAD4 is the output of Hippo-related
signalling, then this suggests that VGLL1–VGLL4 integrate into the
wider Hippo signal transduction network.
VGLLs have been linked to skeletal muscle. Fly vestigial is
implicated in flight muscle development (Bernard et al., 2009). In
mammals, Vgll2 (also known as Vito-1) and Vgll3 (also known as
Vito-2) have been studied in relation to skeletal muscle, especially by
the Braun and Stewart groups (Chen et al., 2004; Gunther et al.,
2004; Maeda et al., 2002; Mielcarek et al., 2002, 2009). Vgll2 has an
important role in adult muscle in vivo, as Vgll2−/−mice have a higher
number of fast-twitch type IIb muscle fibres and downregulation
of the Myh7 slow type I gene (Honda et al., 2017). Vgll3−/− mice
have a sex-linked immune phenotype (Liang et al., 2017) and a
shortened QT interval (http://www.mousephenotype.org/data/genes/
MGI:1920819) but it is unknown whether knockout of Vgll3 affects
myogenesis or adult skeletal muscle. Copy number alterations
of VGLL3 and YAP1 have been reported for human soft tissue
sarcomas including rhabdomoysarcomas, where VGLL3 is required
for proliferation (Cancer Genome Atlas Research Network, 2017;
Hélias-Rodzewicz et al., 2010).
Here, we analyse the regulation and molecular/cellular function of
VGLL3 in skeletal muscle in vitro and in vivo, with reference to the
roles of YAP and TAZ. We report that Vgll3 was expressed at low
levels in healthy muscle but that expression increased both during
muscle hypertrophy and muscle regeneration. In disease settings,
VGLL3 was also highly expressed in dystrophic muscle and alveolar
rhabdomyosarcoma. Vgll3 expression increases as human and
murine myoblasts undergo myogenic differentiation ex vivo. VGLL3
knockdown suppressed myoblast proliferation, while constitutive
VGLL3 expression enhanced myogenic differentiation. However,
adult skeletal muscle fibre types and structure were unaffected in
Vgll3-null mice, presumably due to redundancy and/or feedback
signalling. Proteomics revealed that VGLL3 binds the transcription
factors TEAD1, TEAD3 and TEAD4 in myoblasts and/or myotubes,
but no interactions were detected with major regulatory systems, such
as kinases from various signalling pathways. Transcriptomic analysis
shows that VGLL3 regulates the Hippo negative-feedback loop, and
affects expression of genes controlling myogenesis including Myf5,
Pitx2/3, genes encoding certain Wnts and IGF-binding proteins
(IGFBPs). Thus we conclude that VGLL3 is a transcriptional co-factor
that operates in parallel with the Hippo effectors YAP and TAZ to
control myoblast proliferation and differentiation.
RESULTS
VGLL2 and VGLL3 expression in skeletal muscle and cancer
The Hippo effector YAP, as well as VGLL1 and VGLL4, are able to
bind TEAD family transcription factors (Koontz et al., 2013;
Pobbati et al., 2012). However, although is it known that YAP is
regulated by a plethora of signalling mechanisms, including
phosphorylation, methylation, ubiquitylation, sumoylation and
intracellular localization changes, far less is known about
regulation of VGLLs. We therefore investigated regulation of
VGLL3 and VGLL2, a paralogue that is highly expressed in skeletal
muscle. While VGLL2 is clearly expressed at higher levels in human
muscle, VGLL3 is not (Fig. 1A,B). To examine whether VGLL3
and VGLL2 are regulated transcriptionally, we analysed published
datasets from the GEO (see also Fig. S1) and supplementary
datafiles from published papers. This revealed that VGLL3
expression is >3-fold higher in the quadriceps of boys with
Duchenne muscular dystrophy compared to healthy quadriceps
(Fig. 1C; by contrast, VGLL2 levels are similar between healthy and
Duchenne individuals, see Supplementary Data S1A in Haslett
et al., 2003). There is also robust VGLL3 expression in human fetal
myoblasts (Fig. 1D). In mice, the mean Vgll3 expression increases
both in synergist ablation-loaded hypertrophying plantaris muscle
(Chaillou et al., 2013) and in cardiotoxin-induced regenerating
tibialis anterior muscle (Lukjanenko et al., 2013) (Fig. 1E,F). In
contrast, Vgll2 declines in both situations (Fig. S1).
An earlier study reported that the PAX3-FOXO1 fusion gene
induced Vgll3 expression by 8-fold in the forelimb buds of mouse
embryos at embryonic day (E)10.5 (Lagha et al., 2010). Given that
alveolar rhabdomyosarcomas (ARMS) frequently carry PAX3-
FOXO1 or PAX7-FOXO1 fusion genes, we also analysed VGLL3
expression in ARMS (Missiaglia et al., 2012; Shern et al., 2014).
This showed that average VGLL3 expression is highest in PAX3-
FOXO1 alveolar rhabdomyosarcomas when compared to other
forms of rhabdomyosarcoma, fetal myoblasts or differentiated
muscle (Fig. 1D). Finally, Vgll3 expression is 2.3-fold higher in
mouse embryonal rhabdomyosarcomas caused by YAP1 S127A
expression in activated satellite cells than in control skeletal muscle
(Tremblay et al., 2014).
In mouse muscle, a VGLL2 serine 261 phosphopeptide is
detectable, but no VGLL3 phosphopeptides (Potts et al., 2017).
This is relevant since fly Vestigial is phosphorylated at Ser215 by a
p38 kinase (Pimmett et al., 2017). In humanmuscle, neither VGLL2
nor VGLL3 phosphopeptides are detectable pre- or post-intensive
exercise (Hoffman et al., 2015). Together, this suggests that VGLL3
and VGLL2 are mainly regulated through their protein levels via
transcription, rather than via post-translation modifications.
VGLL3-binding protein partners in murine myoblasts
and myotubes
In fly, Vestigial protein binds the transcription factor scalloped (the
orthoparalogue of mammalian TEAD1– TEAD4) to create ‘wing
cell-specific DNA-binding selectivity’ for Scalloped (Halder and
Carroll, 2001; Halder et al., 1998). VGLL proteins also interact with
the TEAD family of transcription factors; the structure of the core
complex of VGLL1 and TEAD4 reveals that the TONDU domain in
VGLL1 interacts with TEAD4 by forming two interfaces (Pobbati
et al., 2012). Subsequently, VGLL4 has been also shown to pair
with TEAD by forming similar interfaces (Jiao et al., 2014). The
TONDU domains in Drosophila Vestigial and VGLL proteins are
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highly conserved. Thus, the core complex structure of VGLL3 with
TEAD should be similar to that of VGLL1 or VGLL4. To test our
prediction, we modelled the VGLL3–TEAD4 structure using the
PHYRE2 protein fold recognition server. Superimposition of
VGLL1–TEAD4 and VGLL4–TEAD4 crystal structures with the
modelled VGLL3–TEAD4 structure shows that all three binary core
complexes are structurally similar (Fig. 2A). To test experimentally
whether VGLL3 and TEAD2 interact, we overexpressed HA–
TEAD2 with Myc–VGLL3 and their known interactor YAP, in
HEK293 cells and then immunoprecipitated HA–TEAD2, Myc–
VGLL3 or YAP (Fig. 2B). This demonstrated that VGLL3 binds
TEAD2, and that the presence of Myc–VGLL3 reduces binding of
YAP to TEAD2, suggesting that Myc–VGLL3 and YAP compete to
bind HA–TEAD2. By using a fluorescently labelled YAP and
TEAD4, we also verified that VGLL3 directly competes with YAP
(Fig. 2C). Addition of TEAD4 to labelled YAP results in the
formation of a YAP–TEAD4 complex that could be monitored in a
native gel. Introduction of TONDU domain-containing VGLL3
peptide reduces the amount of YAP–TEAD4 complex in a dose-
dependent manner (Fig. 2C), suggesting a direct competition
between YAP and VGLL3 for binding to TEAD4.
To systematically characterise VGLL3-binding proteins in
myogenic cells in a non-biased fashion, we overexpressed and co-
immunoprecipitated VGLL3–Flag from murine C2C12 myoblasts
and myotubes and identified VGLL3-binding proteins through
liquid chromatography and mass spectrometry (LC-MS).
Identification of the bait VGLL3–Flag (Fig. 2D) shows that
immunoprecipitation worked. In addition, identification of
TEAD1 (Fig. 2E), TEAD3 (Fig. 2F) and TEAD4 (Fig. 2G)
confirms that VGLL3 can bind TEAD family transcription factors in
myoblasts and myotubes. Binding to TEAD isoforms was different
depending on the state of myogenic differentiation. The VGLL3–
TEAD1 and VGLL3–TEAD3 interactions did not change overtly
between myoblasts andmyotubes. Interaction between VGLL3with
Fig. 1. VGLL2 and VGLL3 expression in skeletal
muscle and cancer. (A) VGLL2 and (B) VGLL3
expression in different human tissues according to
an analysis of previously published data (G-TEx-
Consortium, 2015). Violin plot with the box showing
the 25–75th percentiles, with the median indicated.
Outliers are excluded. (C) VGLL3 expression in
healthy and Duchenne muscular dystrophy
quadriceps muscle biopsy samples according to
data from Haslett et al. (2003). (D) VGLL3
expression in human skeletal muscle and various
cancers including embryonal rhabdomyosarcoma
(ERMS), fusion gene-negative alveolar
rhabdomyosarcoma (AMRS_NEG), ARMS
expressing PAX3-FOXO1 (ARMS_P3F) or PAX7-
FOXO1 (ARMS_P7F) fusion genes according to
data from Davicioni et al. (2009) and Williamson
et al. (2010). In addition, VGLL3 expression in fetal
myoblasts (FetMyob) at different days (1–3) is
shown. Data is shown as a box plot, where the
box represents the 25–75th percentiles, and the
median is indicated. The whiskers show the 25th
percentile minus 1.5×IQR and 75th percentile plus
1.5×IQR, with dots representing individual values.
(E) Expression of Vgll3 mRNA in mouse plantaris
following synergist ablation according to data from
Chaillou et al. (2013) or (F) regenerating mouse
tibialis anterior muscle following cardiotoxin
injection according to data from Lukjanenko et al.
(2013), where the dotted line indicates levels in
control muscle. a.u., arbitrary units.
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Fig. 2. See next page for legend.
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TEAD4, however, was greater in myotubes, indicating that this
complex likely has a role in the regulation of differentiation.
Importantly, we did not identify other transcription factors among
the co-immunoprecipitated proteins.
VGLL3 interaction proteomics also identified other proteins that
interact with VGLL3 or through which VGLL3 additionally exerts its
function. VGLL3 only bound to eight proteins in C2C12 myoblasts,
but to 52 proteins in C2C12 myotubes. In addition to TEAD1,
TEAD3 and TEAD4 (Fig. 2E–G), VGLL3 also binds these classes of
proteins in myoblasts and/or myotubes (for a full protein list, see
Table S1): (1) heat shock and related proteins (HSP90AA1,HSPA1L,
HSPA8, HSPA9, HSPB1, HSPH1, CRYAB, DNAJA1, DNAJA2
and DNAJB11); (2) tubulins (TUBA1A, TUBB2A, TUBB4B
and TUBB6); (3) metabolic enzymes/proteins (AK1, AKR1B1,
GAPDH and HADHB); (4) mitochondrial channel proteins
(VDAC1, VDAC2, SLC25A11, SLC25A5 and TIMM50); and (5)
Ras-related proteins (RAB10, RAB5A and RALA).
It should be noted however, that heat shock proteins, tubulins and
metabolic proteins, such as GAPDH, are frequently detected in
proteomic studies (Wang et al., 2009) and may be proteins generally
linked to the synthesis and folding of proteins.
We illustrate the functional interaction between VGLL3-binding
proteins for C2C12 myoblasts (Fig. 2H) and C2C12 myotubes
(Fig. 2I). The clear difference in the VGLL3 interactome in
myoblast versus myotubes suggests that the role of VGLL3 in
myogenic differentiation is at least partially regulated by changes in
protein–protein interactions. Most prominent is the differential
interaction with the TEAD isoforms, with VGLL3 interaction with
TEAD1 and TEAD3 in myoblasts, but TEAD1, TEAD3 and,
importantly, TEAD4 in myotubes. This is consistent with our
previous observations showing that Tead4mRNA, and TEAD1 and
TEAD4 protein increase markedly during myogenic differentiation
(Sun et al., 2017). Changes in VGLL3-mediated transcriptional
activation of target genes are thus likely related to this differential
availability of TEAD isoforms. Overall, there was only minimal
overlap with YAP and TAZ-binding proteins with the exception of
TEAD1, TEAD3 and TEAD4 (Table S2 and Sun et al., 2017).
Moreover, most putative binding partners of VGLL3 normally
reside in the cytosol. Whereas many of these proteins are likely
associated with the synthesis of VGLL3, our results might also
mean that VGLL3 can localise to both the nucleus and cytosol. We
used the nuclear export signal-prediction programme NetNes 1.1 to
search for a nuclear export signal in the human VGLL3 amino acid
sequence. This revealed a ‘MQDSLEVTL’ (single amino acid code)
nuclear export signal that was fully conserved between man,
chimpanzee, cat and mouse (Table S3).
Transcriptomic analysis of VGLL3 target gene expression
Given that VGLL3 binds the same TEAD1, TEAD3 and TEAD4
transcription factors that are also bound by YAP and TAZ (Sun
et al., 2017), we next assessed the effect of VGLL3 on gene
expression in murine primary satellite cell-derived myoblasts. We
compared the effects of VGLL3 on gene expression to our previous
transcriptomic examination using YAP1 S127A or TAZ S89A (Sun
et al., 2017). YAP1 S127A/TAZ S89A mutants are constitutively
active because a serine residue is mutated to an alanine so that
YAP or TAZ can no longer be inhibited by Ser127 or Ser89
phosphorylation, respectively, which normally prevents nuclear
localisation. Using a cutoff difference of ≥30% or ≤30% and false
discovery rate (FDR) <10%, we found that VGLL3 only induced the
expression of one gene and downregulated that of nine genes in
myoblasts after 24 h. However, VGLL3 enhanced the expression of
29 genes and lowered expression of 126 genes after 48 h (Fig. 3A; a
full list of VGLL3-regulated genes is given in Table S4). Since
VGLL3 represses 5.2 times as many genes as it induces, this
identifies VGLL3 as a protein that mainly represses its target genes
expression in myoblasts.
As predicted, many of the VGLL3-regulated genes are also
regulated by YAP1 S127A and TAZ S89A (Sun et al., 2017; listed
in Table S5). To illustrate this, we plotted all genes whose
expression was significantly (FDR <10%) upregulated (by ≥30%)
or downregulated (by ≤30%) in response to VGLL3 overexpression.
Many of the genes downregulated by VGLL3 are upregulated by
YAP S127A and vice versa, suggesting an antagonistic effect
(Fig. 3B; Table S5). There are, however, genes that are downregulated
by both YAP1 S127A andVGLL3 (Fig. 3B, lower left). Interestingly,
VGLL3 or YAP1 S127A never induced the same gene (Fig. 3B).
In contrast, VGLL3 and TAZ S89A could both induce the same
genes, but again, there was no clear agonist–antagonist relationship
(Fig. 3C; Table S5).
VGLL3 negatively regulates (≥1.3 fold and FDR <10%) many
crucial genes of the Hippo signal transduction network including
the Hippo transcriptional co-factors Wwtr1 (encoding TAZ: down
by 1.4-fold) and Vgll2 (down by 2.1-fold), in addition to also
suppressing Ajuba, Amotl2 and Frmd6 (down 1.5–1.8 fold)
(Fig. 3A; Tables S4 and S5). As TAZ S89A drives expression of
Vgll2 and Vgll3 (Sun et al., 2017), this suggests that VGLL3, TAZ
and VGLL2 cross-regulate each other. Other downregulated genes
include Fzd4F, the myokine Flst1, the paired-like homeodomain
transcription factors Pitx2 and Pitx3, and the IGFBPs Igfbp2 and
Igfbp4. By contrast, VGLL3 promotes expression of the myogenic
regulatory factor Myf5, the growth factor receptor Egfr, the Wnt
pathway member Wnt7b and the IGFBP Igfbp3 (Fig. 3A and
Tables S4 and S5).
Genes identified as downregulated by VGLL3 overexpression
from our transcriptomic studies in mouse (Fig. 3) were also analysed
in human myoblasts and myocytes using quantitative real-time RT-
PCR (qRT-PCR) after VGLL3 knockdown or overexpression
(Table S6). Most genes deregulated by VGLL3 overexpression in
mouse were validated as also being affected in this human system,
with downregulation of VGLL2, AJUBA, AMOTL2, FSTL1 and
FZD4, with EGFR1 also repressed, whileWWTR1was induced, and
FRMD6 and PITX2/3 were unchanged (Table S6).
VGLL3 expression dynamics and localisation during
myogenesis
To study expression of Vgll2 and Vgll3 in mouse satellite cells and
human primary myoblasts during myogenic progression, we first
performed qRT-PCR.GenerallyVgll2 andVgll3 expression increased
Fig. 2. VGLL3-binding protein partners in murine myoblasts and
myotubes. (A) Superimposition of VGLL1–TEAD4 (PDB ID: 5Z2Q) and
VGLL4–TEAD4 (PDB ID: 4LN0) crystal structures with the modelled VGLL3–
TEAD4 structure. A surface-ribbon representation of TEAD4 is shown in grey.
(B) Expression of VGLL3 in HEK293 cells in an in vitro competition assay
reduces the binding of YAP to TEAD2, suggesting competition between
VGLL3 and YAP for binding to TEAD2. (C) Native gel showing the migration of
free and TEAD4-bound labelled YAP (see diagram on right of gel). Only the
labelled YAP is seen. Upon addition of VGLL3 peptide, the amount of TEAD4-
bound YAP is reduced, with a concomitant increase in the amount of free YAP,
again indicating competition between VGLL3 and YAP for binding to TEAD4.
(D–G) VGLL3–Flag immunoprecipitation (IP) proteomics shows that the
VGLL3 bait is detected (D) and that VGLL3–Flag binds TEAD1, TEAD3 and
TEAD4 in murine C2C12 myoblasts and/or myotubes (E–G). (H) String
analysis of VGLL3–Flag-binding partners identified in C2C12myoblasts and (I)
in C2C12 myotubes. a.u., arbitrary units; LFQ, label-free quantification.
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during myogenic differentiation, with Vgll3 increased in both mouse
and human differentiating myoblasts, while Vgll2 only increased
transiently in mouse (Fig. 4A,B). In humans, VGLL2 is selectively
expressed in skeletal muscle, whereas VGLL3 expression is low in
muscle compared to other tissues (Fig. 1A,B). To analyse protein
distribution, we purchased commercially available anti-VGLL3
antibodies, but found immunolabelling unchanged upon retroviral-
mediated constitutive VGLL3 expression (data not shown). Instead,
we designed a retroviral vector encoding Flag–Vgll3 and used anti-
Flag antibodies to detect the Flag-tagged VGLL3 protein. This
showed that VGLL3was located in both the nucleus and cytoplasm of
C2C12murinemyoblasts (Fig. 4C,D).Uponmyogenic differentiation
Fig. 3. Transcriptomic analysis of VGLL3 target gene expression. (A) Examples of regulation of Hippo-related genes and of genes controlling muscle
functions by VGLL3 versus YAP1 S127A or TAZ S89A in primary murine satellite cell-derived myoblasts at 48 h (FDR <10%). (B,C) In satellite cell-derived
myoblasts, VGLL3 drives expression of genes that are both regulated and unregulated by YAP (B) or TAZ (C), having both agonist and antagonist effects.
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into myocytes and multi-nucleated myotubes, however, there
was a clear and robust nuclear localisation of Flag-tagged VGLL3
(Fig. 4E,F).
VGLL3 supports proliferation and differentiation in mouse
and human myoblasts
To assess VGLL3 function in myoblasts, we first employed siRNA-
mediated downregulation of VGLL3, which significantly reduced
proliferation of both primary murine satellite cell-derived myoblasts
and the human C25Cl48 immortalised myoblast line (Mamchaoui
et al., 2011) (Fig. 5A,B). This was particularly striking in human
myoblasts, where 5-ethynyl-2′-deoxyuridine (EdU) incorporation
after a 2 h EdU pulse dropped from 49.2% to 0.3% when VGLL3
was knocked down (Fig. 5B), suggesting that VGLL3 is essential for
proliferation of human myoblasts. We next evaluated the impact of
VGLL3 knockdown onmyogenic differentiation into multinucleated
myotubes and the assembly of sarcomeres. VGLL3 downregulation
reduced murine myotube formation, as indicated by a drop in the
proportion of nuclei within myotubes (fusion index) from 68.8% to
40.7% (Fig. 5C) and in human myoblasts from 68.8% to 11.2%
(Fig. 5D). However, especially in human myoblasts, the reduced
differentiation measured in VGLL3 downregulated cells may be
largely indirect, being at least partially explained by the presence of
fewer myoblasts owing to their reduced proliferation rate, even
though siRNA-transfected cells were replated at the same density as
controls before inducing differentiation.
We then examined retroviral-mediated overexpression of VGLL3
on proliferation and differentiation in transiently transduced primary
murine satellite cell-derivedmyoblasts and stable VGLL3-expressing
human C25Cl48 immortalised myoblasts. VGLL3 overexpression
did not further increase mouse satellite cell proliferation (Fig. 5E),
but in human myoblasts, the proportion of EdU-positive myoblasts
overexpressing VGLL3 dropped slightly to 26.0%, from 32.8% in
myoblasts transduced with control retrovirus (Fig. 5F). VGLL3
Fig. 4. VGLL3 expression dynamics
and localisation during myogenesis.
(A) Expression of Vgll2 and Vgll3 as
analysed by qRT-PCR in proliferating and
differentiating primary mouse satellite
cell-derived myoblasts or (B) primary
human myoblasts ex vivo. Data are
presented as mean±s.e.m., where n=3
mice or independent experiments. *P<0.05
between proliferation and differentiation
samples (paired two-tailed t-test).
(C,D) Proliferating murine C2C12
myoblasts transduced with (C) control or
(D) Flag–VGLL3-encoding retrovirus, and
immunolabelled for eGFP to identify
transduced cells (from the IRES-eGFP in
the retroviral backbone) and Flag to detect
Flag–VGLL3. (E,F) Differentiated C2C12
myocytes and multinucleated myotubes
transduced with (E) control or (F) Flag–
VGLL3-encoding retrovirus (RV), and
immunolabelled for eGFP and Flag to
detect Flag–VGLL3, showing clear nuclear
localisation of VGLL3. Scale bar: 100 µm.
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overexpression increased the fusion index in mouse satellite cell-
derived myoblasts to 80.4%, from 43.2% with the control (Fig. 5G)
and to 61.0% from 35.4% in human myoblasts (Fig. 5H). Together,
these results in mouse and human myoblasts show that Vgll3
expression enhances myoblast differentiation.
VGLL3-null mice have normal skeletal muscle and myoblast
function
To examine the role of Vgll3 in skeletal muscle development and
maintenance in vivo, we characterised skeletal muscle of hind limbs
of Vgll3−/−mice, generated as part of the International Phenotyping
Consortium (Brown and Moore, 2012). Vgll3−/− mice were viable,
born in the expected Mendelian ratios and did not show any overt
phenotype while reaching adulthood. The extensor digitorum
longus (EDL) and soleus muscles of adult Vgll3−/− mice and
wild-type controls were analysed independently by the London
(Fig. 6) and Munich (Fig. S2 and Table S7) teams. We found no
significant difference between the EDL and Soleus of Vgll3−/− and
wild-type control mice in fibre type distribution (Fig. 6A,D), the
number of satellite cells per muscle fibre (Fig. 6B), and fibre
numbers and size (Fig. 6C,E). This shows that the constitutive loss
of VGLL3 function can be compensated for in vivo, suggesting that
VGLL3 is not essential for normal skeletal muscle development.
Interestingly, satellite cell-derived myoblasts isolated from Vgll3−/−
mice did not show any changes in proliferation rate compared to
wild-type controls, as determined by measuring EdU incorporation
following a 2 h pulse (Fig. 7A,B). Expression of Pax7, myogenin
(Myog), Vgll2 and Vgll4 were also unchanged in Vgll3−/− mice
compared to wild-type controls (Fig. S3). Finally, differentiation
of Vgll3−/− satellite cell-derived myoblasts was assessed by
Fig. 5. Vgll3 supports proliferation and differentiation in mouse and human myoblasts. (A–D) Effects of siRNA-mediated Vgll3 knockdown on cell
proliferation (A,B) and myotube formation (C,D) in primary murine satellite cell-derived myoblasts (A,C) or immortalised human C25Cl48 myoblasts (B,D).
Proliferating mouse or human myoblasts were immunolabelled for (A) myogenin or (B) β-tubulin, and EdU incorporation was measured. (C,D) Myotubes were
visualized by MyHC immunolabelling. (E–H) Effects of retroviral-mediated VGLL3 overexpression on myoblast proliferation (E,F) and myotube formation (G,H) in
both transiently transduced primary murine satellite cell-derived myoblasts (E,G) or stable VGLL3-expressing immortalised human C25Cl48 myoblasts (F,H).
(E,F) Proliferating myoblasts were immunolabelled for GFP (to detect transduced cells from the IRES-eGFP in the retroviral backbone) and EdU incorporation
measured, while (G,H) myotubes were immunolabelled for GFP and MyHC. Reduction of VGLL3 generally inhibits proliferation, while constitutive VGLL3
expression enhances myogenic differentiation. Data are presented as mean±s.e.m., where n=3 mice or independent experiments. *P<0.05 between either si
Vgll3 compared to si Control (A–D), or RV VGLL3 compared to RV Control (E–H) (two-tailed t-test). Scale bars: 100 µm.
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calculating the fusion index to test their ability to form
multinucleated myotubes and measure the area occupied by
MyHC-expressing myotubes, but again no statistically significant
differences were found compared to wild-type controls (Fig. 7C,D).
DISCUSSION
Here, we report a comprehensive analysis of the regulation, protein
binding and effect on target gene expression of the transcriptional
co-regulator VGLL3 in skeletal myogenesis, and compare VGLL3
with YAP and TAZ. Additionally, we characterise VGLL3 function
in skeletal muscle in vitro and in vivo.
Whilst Vgll2 is highly expressed in skeletal muscle and involved
in myogenic differentiation (Chen et al., 2004) and muscle fibre
type distribution (Honda et al., 2017), far less is known about
regulation and function of VGLL3 in adult skeletal muscle.
Generally, Vgll3 is expressed at low levels in healthy muscle, but
levels increase during regeneration (Lukjanenko et al., 2013) and in
mechanically loaded, hypertrophying plantaris muscle (Chaillou
et al., 2013). VGLL3 is also differentially expressed human patients
with muscle-related disease, with a >3-fold increase in quadriceps
muscles of Duchenne muscular dystrophy patients (Haslett et al.,
2003). Copy number gains of the VGLL3 gene have also been
reported for some rhabdomyosarcomas (Hélias-Rodzewicz et al.,
2010) and in sarcomas (Cancer Genome Atlas Research Network,
2017; Hélias-Rodzewicz et al., 2010). Moreover, VGLL3 expression
is high in ARMS associated with PAX3-FOXO1 and PAX7-FOXO1
fusion genes (Missiaglia et al., 2012; Shern et al., 2014) when
compared to other cancers and controls. High expression of VGLL3
in PAX3-FOXO1 fusion gene-positive ARMS is intriguing because
expression of the PAX3-FOXO1 fusion gene in mouse embryos
induces Vgll3 expression in the forelimb bud at E10.5 by 8-fold
(Lagha et al., 2010; Missiaglia et al., 2012; Shern et al., 2014).
Furthermore, a ChIP-Seq analysis of PAX3-FOXO1 target genes
reported VGLL3 as a direct PAX3-FOXO1 target (Cao et al., 2010).
Collectively, this suggests that VGLL3 is controlled at the
transcriptional level when myoblasts proliferate or muscle
hypertrophies. This contrasts with what is found for the Hippo
effectors YAP and TAZ, which are regulated by an extensive Hippo
signal transduction network that regulates via protein modification
(phosphorylation; see Introduction).
In fly, vestigial binds the TEAD homologue scalloped (Halder
and Carroll, 2001; Halder et al., 1998). VGLLs and TEADs also
interact in mammals (Koontz et al., 2013; Pobbati et al., 2012) but
recently ETS1 has been identified as a non-TEAD transcription
factor that can be bound by VGLL3 (Simon et al., 2017). Our
proteomic analysis of VGLL3–Flag-binding proteins in C2C12
myoblasts and myotubes revealed that VGLL3 competes for the
same TEAD1, TEAD3 and TEAD4 transcription factors as bound
by YAP and TAZ in these cells (Sun et al., 2017). The clear
difference in the VGLL3 interactome in myoblast versus myotubes,
however, indicates that the role of this protein in myogenic
differentiation is, in part, regulated by changes in protein–protein
interaction. This includes differential interaction with the TEAD
isoforms, with interaction with TEAD1 and TEAD3 in myoblasts,
but TEAD1, TEAD3 and TEAD4 in myotubes. This is consistent
with previous observations on the expression dynamics of
Tead1–Tead4 mRNA, and TEAD1 and TEAD4 protein, where
TEAD4 levels increase markedly during myogenic differentiation
Fig. 6. Vgll3-null mice have normal
muscle structure and fibre type
content. (A) Extensor digitorum longus
(EDL) or (D) Soleus muscle transverse
sections co-immunolabelled for myosin
heavy chain (MyHC) type I, MyHC type
2a or MyHC type 2b, together with
laminin, from wild-type (WT) or Vgll3−/−
(Vgll3KO)mice. Quantification from such
images reveals no changes in the
proportions of each muscle fibre type.
(B) Quantification of the number of Pax7-
expressing satellite cells per isolated
EDL myofibre in wild-type and Vgll3−/−
mice. (C) EDL or (E) Soleus muscle
transverse sections immunolabelled for
laminin and counterstained with DAPI
from wild-type or Vgll3−/− mice and
corresponding quantification of the total
number of myofibres per muscle,
together with area and Feret diameter of
muscle fibres. Data are presented as
mean±s.e.m. from n=3 mice. *P<0.05
between Vgll3KO and WT (unpaired
two-tailed t-test). Scale bars: 50 µm.
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(Benhaddou et al., 2012; Sun et al., 2017). Indeed, TEAD4
knockdown inhibits myogenic differentiation in satellite cell-
derived myoblasts (Sun et al., 2017). Changes in VGLL3-
mediated activation of target genes between myoblasts and
myotubes are thus likely related to this differential availability of
the TEAD isoforms for activation by VGLL3.
TEAD1, TEAD3 and TEAD4 are the only proteins that are co-
immunoprecipitated together with VGLL3, YAP and TAZ.
Whereas YAP and TAZ share 18.6% of their binding partners,
VGLL3 only shares ∼1% of the binding partners with those for
YAP or TAZ. Moreover, we could only identify the phosphatase
PPP2R1A as a potential protein-modifying regulator among the
VGLL3-binding proteins. Interestingly, PPP2R1A is functionally
relevant in ARMS (Akaike et al., 2018), where VGLL3 is highly
expressed. With VGLL3, we additionally co-immunoprecipitated
many cytosolic proteins, including proteins involved with protein
processing in the endoplasmic reticulum, especially heat-shock
proteins and components of the tubulin cytoskeleton. VGLL3, as
assessed by using a Flag-tagged version, was present in both the
nucleus and cytoplasm in myoblasts, so VGLL3 interaction with
cytoplasmic proteins is likely. We also discovered the presence of a
nuclear export signal in VGLL3. However, heat shock proteins,
tubulins and metabolic proteins, such as GAPDH, are frequently
detected in proteomic studies (Wang et al., 2009) and may be
generally linked to the synthesis and folding of proteins such as
Flag–VGLL3, although others might be false positives, such as
Flag-binding proteins.
Given that VGLL3, YAP and TAZ compete for the same TEAD1,
TEAD3 and TEAD4 transcription factors (Sun et al., 2017), do
VGLL3, YAP and TAZ regulate the same genes as agonists or
antagonists? We compared our new VGLL3 transcriptomic analysis
in myoblasts to our earlier data, where we measured the effect of
YAP1 S127A and TAZ S89A on gene expression (Sun et al., 2017).
This revealed that ∼5 times more genes were downregulated by
VGLL3 than induced, suggesting that VGLL3 acts mainly to reduce
its target gene expression. In the VGLL3 interactome data, however,
we found no obvious binding partner with a known repressor
function. In contrast to VGLL3, YAP induces and represses similar
numbers of genes (Judson et al., 2012; Sun et al., 2017). While there
was a broad overlap between genes regulated by VGLL3, YAP1
S127A and TAZ S89A, there was no simple agonist or antagonist
relationship. For example, VGLL3, YAP1 S127A and TAZ S89A
all repress genes such as Igfbp4. In contrast, the Hippo gene Amotl2
is downregulated by VGLL3 and induced by TAZ S89A and YAP1
S127A, suggesting that VGLL3 and YAP/TAZ act as antagonists in
relation to Amotl2 expression. Most genes deregulated by VGLL3
overexpression in mouse were also similarly affected by VGLL3
overexpression in human myoblasts.
When analysing individual genes, some gene groups and
individual genes stood out. First, VGLL3 mainly downregulated
the YAP-induced Hippo genes Ajuba, Amotl2 and Frmd6, which
are induced by YAP1 S127A, and which we have previously termed
as encoding proteins that together form the Hippo negative-
feedback loop (Judson et al., 2012). Additionally, VGLL3
repressed Vgll2 in man and mouse, and also repressed the Hippo
transcriptional co-factors Wwtr1 (encoding TAZ) in mouse, but
enhancedWWTR1 in man. Differences in effects of VGLL3 on gene
expression between mouse and man can possibly be explained by
complexity of the TEAD transcriptional system. There are four
TEAD transcription factors, YAP, TAZ and four VGLLs. These
factors play a crucial role during myogenic progression (Sun et al.,
2017;Watt et al., 2010) and change expression during differentiation
(Sun et al., 2017 and this study). Such complex regulation also
involves negative-feedback loops regulated by YAP/TAZ and
Fig. 7. Loss of VGLL3 does not affect proliferation or differentiation of satellite cell-derived myoblasts. (A) Primary satellite cells were isolated from the
EDLmuscle of wild-type (WT) orVgll3−/− (Vgll3 KO)mice. Myoblasts were expanded in vitro (onMatrigel) in proliferationmedium and pulsed with EdU for 2 h. EdU
incorporation was visualised and immunolabelling for myogenin performed. (B) Proliferation ofVgll3−/− satellite cells was similar to that of wild-type (WT) controls,
with 48–49%ofmyoblasts incorporating EdU. Therewas a non-significant trend for moremyogenin-positive cells in theVgll3−/− satellite cells compared to control.
(C) EDL Primary satellite cells of WT or Vgll3−/− mice were expanded in vitro (on Matrigel) in proliferation medium and then switched to differentiation
medium for 1 day. Cells were immunolabelled for myosin heavy chain (MyHC), then the fusion index and MyHC-positive area determined. (D) Myotube formation
in Vgll3−/− satellite cells was not significantly different to wild-type control satellite cells, with a fusion index of 64.9% compared to 65.8% in controls. Data are
presented as mean±s.e.m. for n=3 mice. *P<0.05 between Vgll3 KO compared to WT (unpaired two-tailed t-test). Scale bars: 50 µm.
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TEAD1–TEAD4 (Judson et al., 2012). Thus, depending on protein
levels, the state of differentiation, and activity of the negative-
feedback loop, expression of target genes can vary between species.
In addition to the Hippo-related genes, VGLL3 and TAZ S89A
also both induce the myogenic regulatory factor Myf5. This may
be important for embryonic muscle development as the somite
muscle precursor cell marker Pax3 induces Vgll3 (Lagha et al.,
2010). Pax3-positive cells then become myoblasts by expressing
Myf5. Intriguingly, a key enhancer of Myf5 has a TEAD-bound
CATTCC/GGAATG element (Ribas et al., 2011) suggesting a
Pax3–VGLL3–TEAD–Myf5 signalling axis that allows Pax3-
positive precursors to turn into Myf5-expressing myoblasts could
be active in the developing embryo. Future studies should explore
this idea during in vivo embryogenesis.
Other VGLL3-regulated genes in mouse include the myokine
Flst1 (Ouchi et al., 2008) and Egfr, a growth factor receptor
associated especially with embryonal rhabdomyosarcoma (Ganti
et al., 2006). Other targets are theWnt pathway membersWnt7b and
Fzd4, which is relevant given that YAP and TAZ also regulate Wnt
signalling genes or are regulated byWnt members (Park et al., 2015;
Sun et al., 2017). The paired-like homeodomain transcription
factors Pitx2 and Pitx3 which are critical for fetal and regenerative
myogenesis (Knopp et al., 2013; L’Honore et al., 2014) were also
expressed at lower levels in myoblasts overexpressing VGLL3, as
were the IGFBPs IGFBP2 and IGFBP4, which fine-tune IGF-1
signalling (Allard and Duan, 2018). In summary, VGLL3 acts
mainly to repress gene expression, for example acting on the genes
comprising the Hippo negative-feedback loop, and regulating genes
such as Myf5 that control the muscle lineage.
After analysing the molecular regulation and function of VGLL3,
we tested the effect of VGLL3 gain- and loss-of-function on
mouse and human myoblasts, as well as the skeletal muscle
phenotype of Vgll3−/−mice. Here, the most striking result is that the
knockdown of VGLL3 in human myoblasts almost completely
blocks proliferation. A link between VGLL3 and proliferation at
least in some cell types may explain the high expression, copy
number gains and function of VGLL3 in sarcomas, including
rhabdomyosarcomas (Cancer Genome Atlas Research Network,
2017; Hélias-Rodzewicz et al., 2010). Suppression of the Hippo
negative-feedback loop by VGLL3 also places VGLL3 as a
promoter of proliferation. Conversely, VGLL3 has been reported
to act as a tumour suppressor in epithelial ovarian cancer (Gambaro
et al., 2013). This might reflect that VGLL3 can have both
proliferation-promoting oncoprotein or pro-differentiation tumour
suppressor effects. Indeed, we found that overexpression of VGLL3
at a later time point promotes the differentiation of both mouse and
human myoblasts. This is reminiscent of what is seen for TAZ
(Mohamed et al., 2016; Sun et al., 2017), which can also switch
from a pro-proliferation to a pro-differentiation regulator.
Given the molecular regulation and function of VGLL3 and its
role in myoblast proliferation and differentiation, it is surprising that
Vgll3−/− mice develop apparently normally without a detectable
skeletal muscle phenotype. However, a sex-linked autoimmunity
phenotype has been reported recently for Vgll3−/− mice (Liang
et al., 2017). Reasons for the lack of a major phenotype in vivo could
be the redundancy among TEAD family-targeting transcriptional
co-regulators and the potent Hippo negative-feedback loop, which
also operates in skeletal muscle cells (Judson et al., 2012). This
feedback loop also probably prevents a major phenotype when the
mouse Yap1 gene is mutated in the genome so that the serine 112
phosphorylation site is mutated into an alanine (Chen et al.,
2015). Similarly, we found no overt muscle phenotype inWwtr1−/−
(TAZ-null) mice (Sun et al., 2017). Redundancy between YAP,
TAZ and VGLL1–VGLL4 may be important to prevent
the mutation of a single gene causing the breakdown of an organ
system. Here, a good example are the myogenic regulatory factors
MyoD1 and Myf5 whose individual knockout has little effect
on skeletal muscle development, but whose combined knockout
essentially halts functional myogenesis (Kassar-Duchossoy et al.,
2004; Rudnicki et al., 1993).
MATERIALS AND METHODS
Ethics statement for animal experimentation
Mice were bred in accordance with British law under the provisions of the
Animals (Scientific Procedures) Act 1986, as approved by the King’s
College London Ethical Review Process committee. Wild-type mice were
C57BL/10. Vgll3-knockout mice (VGLL3-DEL890INS2-EM1-B6N) were
provided by the MRC (The Mary Lyon Centre, MRC Harwell Institute,
UK). Vgll3-knockout mice had been engineered using the CRISPR/Cas9
technology to induce a deletion of 890 nucleotides from the Vgll3 gene
(including the functionally critical exon 2) to induce a premature stop codon
and a null allele (C57BL/6NtTac genetic background).
Analysis of published datasets
We downloaded several gene expression datasets from Gene Expression
Omnibus (GEO) to evaluate whether challenges or disease affect Vgll3
expression. These include dataset GDS4932 for gene expression in synergist
ablation-overloaded, hypertrophying mouse plantaris muscle (Chaillou
et al., 2013), dataset GDS4924 for regeneration after cardiotoxin-induced
muscle injury of mouse tibialis anterior muscle (Lukjanenko et al., 2013)
and dataset GDS612 from quadriceps skeletal muscle biopsies from DMD
patients and unaffected control individuals (Haslett et al., 2003). Moreover,
we used supplementary data files from studies comparing resting, resistance
exercise or endurance exercise-trained human muscle (Vissing and
Schjerling, 2014), investigating the effect of high-intensity exercise on the
human muscle phosphoproteome (Hoffman et al., 2015) and investigating
the effect of maximal contractions on the mouse muscle phosphoproteome
(Potts et al., 2017). To examine VGLL3 expression in cancer, we analysed
gene expression in 235 rhabdomyosarcoma (RMS) patients from two
publicly available datasets: containing 101 samples [Innovative Therapies
for Children with Cancer/Carte d’Identite des Tumeurs (ITTC/CIT)]
(Williamson et al., 2010), and 134 RMS samples [Children’s Oncology
Group/Intergroup Rhabdomyosarcoma Study Group (COG/IRSG)]
(Davicioni et al., 2009).
Modelling VGLLs binding to TEAD4 transcription factor
The structure of VGLL3 in the VGLL3–TEAD4 complex was predicted
using the Phyre2 protein fold recognition server (Kelley et al., 2015). Phyre2
predicts the three-dimensional structure of the protein using its primary
sequence. A model of the TONDU motif of VGLL3 was built using
homology detection methods. The homologous crystal structure of the
VGLL1–TEAD4 complex (PDB ID: 5Z2Q) was used in the prediction, and
the confidence score of the predicted VGLL3 model is 99.8%. In Fig. 2A,
the predicted VGLL3 model was overlaid on crystal structures of the
VGLL1–TEAD4 complex (PDB ID: 5Z2Q) and VGLL4–TEAD complex
(PDB ID: 4LN0). Only one TEAD is shown for clarity.
In vitro cell culture
Immortalized human myoblasts (C25Cl48) were provided by Dr Vincent
Mouly, Institute Myology, Paris, France (Mamchaoui et al., 2011).
Proliferating human myoblasts were maintained in skeletal muscle cell
growth medium (Promo-Cell, C-23160) supplemented with 20% FBS
(Gibco). To induce differentiation, myoblasts were switched to the skeletal
muscle cell differentiation medium (Promcell: C-23161). Proliferation and
differentiation medium were supplemented with 50 µg/ml Gentamycin.
Mouse C2C12 myoblasts and HEK293T cells were cultured in DMEM
(Sigma), supplemented with 10% FBS (Gibco). To induce differentiation,
C2C12 myoblasts were cultured in growth medium until confluence, then
the medium was switched to DMEM with 2% horse serum (Gibco).
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Competitive binding assay
HEK293 cells were grown in RPMI supplemented with 10% FBS at 37°C in
5% CO2. HEK293 cells were transfected with HA–TEAD2 and/or Myc–
VGLL3, as indicated. The tags were introduced to the 5′ end through
modification of the pCI-neo vector (Promega). Constructs were transfected
using Lipofectamine 2000. At 24 h post transfection, the cells were lysed in
buffer with 20 mM Tris-HCl pH 8.0, 150 mMNaCl and 0.1% Triton X-100
and protease inhibitors. HA–TEAD2 was immunoprecipitated using anti-
HA beads (Sigma) and the co-immunoprecipitated YAP was detected using
anti-YAP antibody (D8H1X, Cell Signaling). HA–TEAD2 was detected
using anti-HA-HRP (Sigma) and Myc–VGLL3 was detected using clone
4A6 antibody (Millipore). For full details of antibodies, see Table S8.
Labelled human YAP (amino acids 61–100) and unlabelled human
VGLL3 (amino acids 86–112) peptides were used. Histidine-tagged human
TEAD4 (amino acids 217–434) was expressed in E.coli and purified by
using immobilized metal affinity chromatography (IMAC) and gel filtration
chromatography. TEAD4 was incubated with an increasing concentration of
VGLL3 peptide prior to the addition of labelled YAP. After a 10-min
incubation at room temperature, a native gel (10%) was run at 100 V to
visualize free and TEAD-bound YAP.
Proteomics
The preparation of samples and analysis was performed as described
previously (Sun et al., 2017). Briefly, C2C12 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS) and 4 mM glutamine. For immunoprecipitation, 80,000
C2C12 cells were seeded per 10 cm dish. The following day, the cells were
transduced with control or Vgll3-encoding retroviral supernatant. The next
day, transduction was confirmed by assessing the presence of green
fluorescent protein (GFP) from an IRES-eGFP in the retroviral backbone.
Successful immunoprecipitation of Flag-VGLL3 was also confirmed by
immunoprecipitation followed by western blotting using anti-Flag antibody
(Sigma, F7425) (data not shown). Cells were split either into proliferation or
differentiation conditions (72 h). Proliferating or differentiated cells were
then washed on ice with PBS, and collected in lysis buffer (150 mM NaCl,
20 mM Tris-HCl pH 7.5, 1% Triton X-100) with 1 mM sodium
orthovanadate, protease inhibitor cocktail (Sigma, p8340), and
phenylmethylsulfonyl fluoride (PMSF) (Sigma). Lysates were incubated
for 1 h on ice and centrifuged at 11,000 g at 4°C for 5 min and supernatant
incubated at 4°C with anti-FlagM2magnetic beads (Sigma, M8823). Beads
were washed three times with washing buffer (150 mM NaCl, 20 mM Tris-
HCl pH 7.5). Sample preparation/mass spectrometry were performed as
described previously (Turriziani et al., 2014). The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium
via the PRIDE (Perez-Riverol et al., 2015; Vizcaíno et al., 2016) partner
repository with the dataset identifier PXD012040.
Gene expression
Primary murine myoblasts (isolated as described in Sun et al., 2017) were
transduced with VGLL3-encoding retrovirus for 24 h or 48 h, with empty
vector retrovirus as control. RNA was isolated using TRIzol (ThermoFisher
Scientific) followed by purification and DNase digestion using RNeasy
minikits (Qiagen, Venlo, Netherlands). Quantification of total RNA was
performed on a Nanodrop spectrophotometer (ThermoFisher Scientific) and
quality tested on an Agilent Tapestation with R6K Screentapes (RIN 7.6-9.8).
Generation of sense-strand cDNA from purified total RNA followed by
second-strand synthesis, in vitro transcription cRNA synthesis, single-
stranded cDNA synthesis and RNA hydrolysis, fragmentation and labelling,
was performed according to manufacturer’s instructions (GeneChip WT Plus
reagent kit, Affymetrix, Santa Clara, CA). Hybridisation, washing, staining
and scanning of microarrays were carried out on Affymetrix Mouse Gene 2.0
ST microarrays using a GeneChip Fluidics station 450 and GCS3000 scanner
(Affymetrix®, Santa Clara, CA).
Data pre-processing and quality control analysis was performed using
Affymetrix® Genechip® Expression Console v1.2. Probe cell intensity data
on the Mouse Gene 2.0 ST array (CEL files) were processed using the
RMA16 algorithm (Affymetrix, Santa Clara, CA), which fits a robust linear
model at probe level by employing background correction, quantile
normalisation of log2-transformed data and summarisation to probe level
data for primary quality control analysis. Experiments and analysis were
performed in triplicate at Centre for Genome Enabled Biology andMedicine
(University of Aberdeen, Aberdeen, UK). Microarray data is available via
ArrayExpress accession E-MTAB-7614.
Data were analysed in Partek® Genomics Suite®, version 6.6, build
6.15.0730 Copyright©; 2014 (Partek Inc., St Louis, MO) using a Mouse
gene Gene 2.0 ST annotation file from build mm10, MoGene-2.0-st-
v1.na35.mm10.transcript. Affymetrix CEL files were imported to Partek®
Genomics Suite®, and data processed using robust multiarray averaging
(RMA) normalisation with RMA background correction and quantile
normalisation of log2-transformed data and probeset summarisation by
median polish. Two-way analysis of variance with time point (24 h, 48 h)
and transcription factor (empty vector, VGLL3, YAP1 S127A, TAZ S89A)
groups and time×transcription interaction was performed to evaluate
significantly differentially expressed genes. YAP1 S127A and TAZ S89A
(Sun et al., 2017) were included to allow comparison between VGLL3 and
these Hippo pathway TEAD co-factors. The fold change for each gene in
myoblasts expressing TAZ S89A, YAP S127A or VGLL3 compared to in
myoblasts expressing empty vector, as a baseline, at each time point was
calculated using the geometric mean of samples in each group with
significance calculated by means of a Fisher’s Least significant difference
test. Genes with fold change of≥1.3 fold and FDR of 10% in VGLL3 versus
empty vector were further evaluated. The gene expression analysis was
performed with the full set of samples (Empty Vector, VGLL3) and
previously published YAP1 S127A and TAZ S89A results (Sun et al., 2017).
Myofibre isolation and culture of mouse satellite cells
Mice aged between 8–12 weeks were killed by cervical dislocation and the
extensor digitorum longus (EDL) muscles were isolated and digested as
previously described (Judson et al., 2012). Freshly isolated myofibres were
fixed in 4% PFA for 10 min, or plated on Matrigel, and the satellite cell-
derived myoblasts were then expanded using DMEM-GlutaMAX
(Invitrogen), with 30% FBS (Gibco), 10% horse serum (Invitrogen Life
Technologies), 1% chick embryo extract (MP), 10 ng/ml bFGF (PreproTech)
and 1% penicillin–streptomycin (Sigma), again as previously described
(Moyle and Zammit, 2014).
Isolation and culture of primary human myoblasts
Primary humanmyoblasts were obtained from biopsies of the vastus lateralis
of consenting individuals [approved by the UK National Health Service
Ethics Committee (London Research Ethics Committee; reference 10/
H0718/10 and in accordance with the Human Tissue Act and Declaration of
Helsinki)]. Biopsies were digested in basal medium (PromoCell containing
collagenase B and dispase II) and single cells isolated via a 100 µm cell
strainer as previously described (Agley et al., 2015). Adherent cells were
cultured for 7 days in skeletal muscle cell growth medium (PromoCell,
Heidelberg, Germany) and the NCAM/CD56+ myogenic population
collected via magnetic-activated cell sorting (MACS).
Retroviral expression vectors
The retroviral backbone pMSCV-puro (Clontech) was modified to replace
the puromycin selection gene with an IRES-eGFP sequence to create
pMSCV-IRES-eGFP, which served as control. Mouse Vgll3 cDNA was
amplified through a RT-PCR and cloned into pMSCV-IRES-eGFP to
generate RV VGLL3. Retrovirus was then packaged in 293T cells using
standard methods. Proliferating satellite cells were transduced in six-well
plates with 500 μl of retrovirus in 1.5 ml of proliferation medium with
polybrene (4 μg/ml).
Mouse Vgll3 cDNA (transcript variant XM_006523098.2, which
encodes a protein of 276 amino acids) was amplified by RT-PCR and
cloned into pMSCV-IRES-eGFP to generate a 3xFlag-VGLL3 retrovirus.
The human cDNA of VGLL3 (transcript VGLL3-201, which encodes a
protein of 320 amino acids) was cloned by RT-PCR from a plasmid
provided by TransOMIC technologies (MGC premier cDNA clone for
VGLL3: BC094780) into pMSCV-IRES-eGFP to generate RV VGLL3.
Retrovirus (control; empty vector encoding only for GFP, and retrovirus
containing VGLL3) were then packaged in Phoenix cells using standard
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methods. Proliferating immortalized human myoblasts (C25Cl48) were
transduced in six-well plates with 200 μl of concentrated retrovirus in 1.8 ml
of proliferation medium with polybrene (8 μg/ml). Cells were expanded and
GFP-positive cells (transduced cells) were FAC sorted and expanded in vitro
for a few days when stably transduced cells were analysed.
siRNA-mediated gene knockdown
Transfection of siRNA into primary satellite cell-derived murine
myoblasts from EDL myofibres was performed with Silencer select Pre-
designed siRNA (Invitrogen Life Technologies) using Lipofectamine
RNAiMAX. The siRNAs were: Ambion, siVGLL3 (silencer selected
siRNA ID: s91841) and Silencer Select Negative Control #2 siRNA
(4390847). Satellite cells were transfected with siRNA at a final
concentration of 10 nM in DMEM-GlutaMAX, 30% FBS, 10% horse
serum and 1% chick embryo extract for 24 h at 37°C. Transfection of
siRNA into immortalized human myoblasts (C25Cl48) was performed
with FlexiTube GeneSolution (four siRNAs targeting the gene of interest)
(Qiagen) using Lipofectamine RNAiMAX. The siRNAs used against
VGLL3 were Hs_VGLL3_1, SI03180310, Hs_VGLL3_3, SI03236233,
Hs_VGLL3_4, SI04232312, Hs_VGLL3_5, SI104277819 (Qiagen) and
the All Stars Negative control siRNA. Human myoblasts were transfected
with a mix of 4 siRNA targeting VGLL3 and each individual siRNA used
at a final concentration of 2 nM in skeletal muscle cell growth medium
(Promo-Cell) for 24 h at 37°C.
qRT-PCR
Primary satellite cell-derived murine myoblasts isolated from EDL muscle
or primary human myoblasts obtained from biopsies of the vastus lateralis
were cultured in six-well plates in proliferation medium or switched to
differentiation medium for different periods of time (12, 24, 48 or 72 h).
Total RNA was extracted using the RNeasy Kit (Qiagen) and cDNA
prepared from 500 ng to 1 μg of RNA with the QuantiTect Reverse
Transcription Kit with genomic DNA wipeout (Qiagen). qRT-PCR was
performed on aMx3005PQPCR system (Stratagene) with Brilliant II SYBR
green reagents and ROX reference dye (Stratagene) using primers shown in
Table S9. Relative expression between proliferating and differentiated
myoblasts was measured in three replicates and significance was tested with
a two-tailed Student’s t-test using Microsoft Excel.
Muscle cryosectioning and immunolabelling
EDL and Soleus muscles were harvested and frozen in liquid nitrogen-
cooled isopentane. Frozen sections (10 µm) were cut on a cryostat, then
dried and kept at −80°C before analysis (Ortuste Quiroga et al., 2016).
Slides were allowed to warm up at room temperature, washed with PBS for
5 min and then blocked in 5% goat serum, 0.5% BSA and 0.2% triton
X-100/PBS for 30 min. Primary antibodies (Table S8) were prepared in
blocking solution and incubated overnight at 4°C. Sections were washed in
0.05% Tween 20/PBS and secondary antibodies (Molecular Probes; 1:500)
were prepared in blocking solution and applied for 1 h at room temperature.
Preparations were then washed in 0.05% Tween 20 (Merck) in PBS and then
incubated in DAPI (300 µM) for 10 min, washed in PBS and mounted in
Dako fluorescence mounting medium.
Immunolabelling of cells
EdU incorporation was performed using a Click-iT EdU Imaging Kit
(Invitrogen Life Technologies) as per the manufacturer’s instructions.
Primary murine satellite cell-derived myoblasts and C2C12 myoblasts
were immunolabelled as previously described (Judson et al., 2012).
Briefly, fixed myoblasts were permeabilised with 0.5% Triton X-100 in
PBS for 5 min at room temperature and blocked with 5% goat serumin
PBS for 60 min at room temperature. Primary antibodies [e.g. anti-Flag
(F1804, Sigma), anti-MyHC (MF20, DSHB) and anti-Myogenin (F5D,
DSHB); details are given in Table S1] were applied overnight at 4°C, and
then cells were washed and visualised with fluorochrome-conjugated
secondary antibodies (Invitrogen) used at 1:500 for 1 h at room
temperature. Preparations were then incubated in DAPI (300 µM) for
10 min and washed in PBS.
Image acquisition
Images of platedmyoblasts andmuscle cross-sections were acquired on a Zeiss
Axiovert 200M microscope using a Zeiss AxioCam HRm and AxioVision
software version 4.4 (Zeiss). Images were adjusted globally for brightness and
contrast. Images of whole muscles were reconstructed from several pictures
using Adobe Photoshop software (Fig. 6) and analysed (cell number counting,
muscle fibre area and Ferret diameter) with ImageJ software.
Statistical testing
Cells in multiple unit areas per experimental condition well were analysed,
and all data from each of at least three mice or independent wells are
expressed as a mean±s.e.m. A significant difference (P<0.05) between
control and a test sample was determined using a two-tailed t-test in Excel
(Microsoft).
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